Dicerna Pharma (DRNA) Tops Q3 EPS by 24c

Dicerna Pharma (NASDAQ: DRNA) reported Q3 EPS of ($0.22), $0.24 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $63 million versus the consensus estimate of $43.78 million.

For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c